5:38 PM
Jun 17, 2013
 |  BC Extra  |  Top Story

SCOTUS: pay-for-delay subject to antitrust litigation

The U.S. Supreme Court ruled on Monday in Federal Trade Commission v. Actavis Inc., et al. that pay-for-delay settlements between branded and generic drug manufacturers are not immune from antitrust litigation. The decision overturns a ruling by...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >